Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Stelara

Phase 2Biologic

BBiocon Biologics UK PLC

Stelara is one of 12 biologic programs targeting LAM. It is currently in Phase 2.

1

Indications

13

Total Trials

2

Active Trials

11

Competitors

Pipeline

Status by Indication[3][1]

Indication

LAMRecruiting

LAMPhase 2

Recruiting

Competition

Competitive Landscape

12 competitors in LAM

#DrugCompanyPhaseTrials

Kesimpta

Rituxan

Budesonide/formoterol

Humira

Boehringer Ingelheim

Kineret

Cosentyx

Johnson & Johnson

Stelara

BBiocon Biologics UK PLC

Roactemra

KKarolinska Institutet

Colesevelam Hcl

NAGLAZYME

BioMarin Pharmaceutical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Psoriasis8 trials

Efficacy, Safety, and Immunogenicity of AVT04 With Moderate-to-Severe Chronic Plaque Psoriasis

Completed·AAlvotech Swiss AG·Phase 3·NCT04930042·581 enrolled

A Study to Compare the Efficacy and Safety of CT-P43 to Stelara in Patients With Plaque Psoriasis

Completed·CCelltrion·Phase 3·NCT04673786·509 enrolled

Comparing Efficacy and Safety of Bmab 1200 and Stelara in Patients With Moderate to Severe Chronic Plaque Psoriasis

Completed·BBiocon Biologics UK PLC·Phase 3·NCT05335356·384 enrolled

Show 5 more trials

Efficacy, Safety, and Immunogenicity of Subcutaneous DMB-3115 Versus Stelara® in Patients With Moderate to Severe Chronic Plaque Psoriasis

Completed·DDong-A ST Co., Ltd.·Phase 3·NCT04785326·598 enrolled

An Efficacy and Safety Study of GNR-068 (Ustekinumab Biosimilar) and Stelara® in the Treatment of Patients With Moderate to Severe Plaque Psoriasis

Active, not recruiting·AAO GENERIUM·Phase 3·NCT06488664·422 enrolled

A Study to Compare SB17 (Proposed Ustekinumab Biosimilar) to Stelara® in Subject With Moderate to Severe Plaque Psoriasis

Completed·SSamsung Bioepis Co., Ltd.·Phase 3·NCT04967508·503 enrolled

A Double-blind Study to Compare the Efficacy, Safety, and Immunogenicity of the Proposed Biosimilar Ustekinumab FYB202 to Stelara® in Patients With Moderate-to-Severe Plaque Psoriasis

Completed·BBioeq GmbH·Phase 3·NCT04595409·392 enrolled

Comparative Study of BAT2206 With Stelara® in Patients With Moderate to Severe Plaque Psoriasis

Completed·BBio-Thera Solutions·Phase 3·NCT04728360·556 enrolled

Tics2 trials

A Safety and Pharmacokinetics Study of Ustekinumab Biosimilar GNR-068 and Stelara® in Healthy Volunteers

Completed·AAO GENERIUM·Phase 1·NCT06481215·122 enrolled

Comparative Study to Evaluate the Pharmacokinetics of BAT2206 vs Stelara® in Healthy Subjects

Completed·BBio-Thera Solutions·Phase 1·NCT04371185·270 enrolled

Oral1 trial

Study Evaluating PK of Ustekinumab Administered Orally Via RaniPill™ Capsule

Completed·RRANI Therapeutics·Phase 1·NCT05890118·55 enrolled

Immunodeficiency1 trial

Study of Safety, Tolerability, and Efficacy of Ustekinumab for Symptomatic Gastrointestinal Inflammation Associated With Common Variable Immunodeficiency

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1/2·NCT02199496·5 enrolled

LAM1 trial

Personalized Therapies in Inflammatory Complex Disease

Recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 2·NCT03651518·32 enrolled

Sources

References

[1]
ClinicalTrials.gov — 13 trial records for Stelara. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Stelara compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Stelara. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Biocon Biologics UK PLC company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: BBiocon Biologics UK PLC

Related News